Free Trial

Retirement Systems of Alabama Purchases 14,069 Shares of Bruker Co. (NASDAQ:BRKR)

Bruker logo with Computer and Technology background

Retirement Systems of Alabama lifted its position in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 11.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 134,254 shares of the medical research company's stock after purchasing an additional 14,069 shares during the period. Retirement Systems of Alabama owned 0.09% of Bruker worth $9,272,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. First Horizon Advisors Inc. increased its holdings in shares of Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company's stock worth $25,000 after purchasing an additional 218 shares in the last quarter. True Wealth Design LLC lifted its position in Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock valued at $36,000 after purchasing an additional 510 shares during the period. UMB Bank n.a. boosted its holdings in Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company's stock worth $46,000 after purchasing an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd purchased a new stake in Bruker during the 2nd quarter valued at $52,000. Finally, GAMMA Investing LLC grew its holdings in shares of Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company's stock worth $60,000 after acquiring an additional 388 shares during the period. 79.52% of the stock is owned by institutional investors.

Bruker Trading Up 1.1 %

Shares of BRKR traded up $0.63 during trading hours on Tuesday, reaching $57.81. 1,643,778 shares of the company traded hands, compared to its average volume of 1,116,029. The stock's fifty day moving average price is $58.66 and its 200 day moving average price is $62.65. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. The firm has a market cap of $8.76 billion, a price-to-earnings ratio of 27.79, a PEG ratio of 4.00 and a beta of 1.18. Bruker Co. has a 12-month low of $48.07 and a 12-month high of $94.86.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The company had revenue of $864.40 million during the quarter, compared to analysts' expectations of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. Bruker's quarterly revenue was up 16.4% on a year-over-year basis. During the same period last year, the firm earned $0.74 earnings per share. Sell-side analysts forecast that Bruker Co. will post 2.4 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date of this dividend was Monday, December 2nd. Bruker's payout ratio is 9.62%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. TD Cowen cut their target price on shares of Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group upgraded Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price target for the company in a research note on Thursday, December 5th. Barclays lowered their target price on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company reduced their price objective on Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 6th. Finally, UBS Group assumed coverage on shares of Bruker in a report on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price target for the company. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $74.70.

Read Our Latest Analysis on BRKR

Insider Activity

In other Bruker news, CEO Frank H. Laukien acquired 100,000 shares of Bruker stock in a transaction that occurred on Monday, November 18th. The stock was bought at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the purchase, the chief executive officer now directly owns 38,439,563 shares of the company's stock, valued at approximately $1,927,359,688.82. This represents a 0.26 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 28.30% of the company's stock.

About Bruker

(Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Featured Stories

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Should you invest $1,000 in Bruker right now?

Before you consider Bruker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.

While Bruker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

UnitedHealth Group: A Healthcare Giant with Strong Dividends

UnitedHealth Group: A Healthcare Giant with Strong Dividends

UnitedHealth Group (UNH) is a powerhouse in healthcare, offering an impressive 14.7% average annual dividend increase over the last three years.

Related Videos

Inflation-Busting Dividends: 3 Stocks Raising Payouts 4X Faster

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines